Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.30
MACK's Cash to Debt is ranked higher than
57% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. MACK: 1.30 )
MACK' s 10-Year Cash to Debt Range
Min: 0.8   Max: No Debt
Current: 1.3

Equity to Asset -0.53
MACK's Equity to Asset is ranked higher than
50% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MACK: -0.53 )
MACK' s 10-Year Equity to Asset Range
Min: -4.85   Max: 0.24
Current: -0.53

-4.85
0.24
F-Score: 3
Z-Score: -3.40
M-Score: -5.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -116.57
MACK's Operating margin (%) is ranked higher than
70% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. MACK: -116.57 )
MACK' s 10-Year Operating margin (%) Range
Min: -2220.11   Max: -189.58
Current: -116.57

-2220.11
-189.58
Net-margin (%) -139.10
MACK's Net-margin (%) is ranked higher than
69% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. MACK: -139.10 )
MACK' s 10-Year Net-margin (%) Range
Min: -2284.59   Max: -186.58
Current: -139.1

-2284.59
-186.58
ROA (%) -59.25
MACK's ROA (%) is ranked higher than
61% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. MACK: -59.25 )
MACK' s 10-Year ROA (%) Range
Min: -110.9   Max: -71.71
Current: -59.25

-110.9
-71.71
ROC (Joel Greenblatt) (%) -670.48
MACK's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. MACK: -670.48 )
MACK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1483.52   Max: -1183.68
Current: -670.48

-1483.52
-1183.68
» MACK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

MACK Guru Trades in Q4 2012

Steven Cohen Sold Out
» More
Q1 2014

MACK Guru Trades in Q1 2014

Murray Stahl 12,000 sh (New)
» More
Q2 2014

MACK Guru Trades in Q2 2014

Jim Simons 569,413 sh (New)
Paul Tudor Jones 13,622 sh (New)
Murray Stahl 12,000 sh (unchged)
» More
Q3 2014

MACK Guru Trades in Q3 2014

Murray Stahl 12,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 321,213 sh (-43.59%)
» More
» Details

Insider Trades

Latest Guru Trades with MACK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 13.70
MACK's P/S is ranked higher than
79% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. MACK: 13.70 )
MACK' s 10-Year P/S Range
Min: 1.79   Max: 16.53
Current: 13.7

1.79
16.53
EV-to-EBIT -11.50
MACK's EV-to-EBIT is ranked higher than
51% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MACK: -11.50 )
MACK' s 10-Year EV-to-EBIT Range
Min: -12.1   Max: -0.5
Current: -11.5

-12.1
-0.5
Current Ratio 1.34
MACK's Current Ratio is ranked higher than
54% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. MACK: 1.34 )
MACK' s 10-Year Current Ratio Range
Min: 1.14   Max: 4.51
Current: 1.34

1.14
4.51
Quick Ratio 1.34
MACK's Quick Ratio is ranked higher than
57% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. MACK: 1.34 )
MACK' s 10-Year Quick Ratio Range
Min: 1.14   Max: 4.51
Current: 1.34

1.14
4.51

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.56
MACK's Price/Median PS Value is ranked higher than
77% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. MACK: 1.56 )
MACK' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 1.51
Current: 1.56

0.21
1.51
Earnings Yield (Greenblatt) -8.70
MACK's Earnings Yield (Greenblatt) is ranked higher than
70% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. MACK: -8.70 )
MACK' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -8.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:MP6.Germany,
Merrimack Pharmaceuticals Inc was incorporated in the Commonwealth of Massachusetts in 1993 and reincorporated under the laws of the State of Delaware in October 2010. The Company is a biopharmaceutical company engaged in discovering, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer. Its core approach to systems biology is to apply multidisciplinary and multi technology capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks, that allow to engineer treatments that are directed at the mechanisms of disease. The Company currently has six targeted therapeutic oncology candidates in clinical development, are either monoclonal antibodies or monoclonal antibody-derived molecules that are designed to block oncogenic signaling pathways, such as MM-121, MM-111, MM-151 and MM-141, or nanotherapeutics, such as MM-398 and MM-302, that are designed to preferentially deliver cytotoxic therapies to the tumor tissue. MM-398 is a novel, stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 is designed to stably retain and protect irinotecan while in circulation in the body and enable efficient accumulation of the drug in solid tumors. Its Phase 3 clinical trial of MM-398 is focused on pancreatic cancer, and used in a number of other solid tumor indications, including colorectal cancer, lung cancer, breast cancer, glioma and pediatric solid tumors. Its MM-121 is a fully human monoclonal antibody that targets the ErbB3 cell surface receptor. MM-121 is designed to inhibit cancer growth directly, restore a tumor's sensitivity to drugs to which it has become resistant, and delay the development of resistance by a tumor to other agents. Its MM-111 is a bispecific antibody designed to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 (HER2) cell surface receptor. MM-111 is designed to anchor to both receptors, ErbB2 (HER2) and HER3, on the cell surface and block heregulin's ability to transmit tumor growth signals, thus inhibiting the tumor cell's ability to thrive. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. It is designed to target and bind to cancer cells that overexpress ErbB2 (HER2) and thereby release doxorubicin at the site of the tumor, while minimizing uptake into normal cells, including those of the heart. MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of EGFR (ErbB1). MM-151 is in its Phase 1 clinical trial for patients with refractory solid tumors. Its MM-141 is a fully human tetravalent bispecific antibody designed to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth
» More Articles for MACK

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Starbucks Corp, KD Supply Holdings Inc, Capital One Financial Corp, Merr Dec 14 2014 

More From Other Websites
Merrimack Pharmaceuticals Announces the Addition of Russell T. Ray to Its Board of Directors Dec 17 2014
MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Dec 17 2014
Merrimack Pharmaceuticals Announces the Addition of Russell T. Ray to Its Board of Directors Dec 17 2014
Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer... Dec 12 2014
Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer... Dec 12 2014
Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398,... Dec 04 2014
Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398,... Dec 04 2014
Merrimack Pharmaceuticals to Present at Oppenheimer 25th Annual Healthcare Conference, Hold Analyst... Dec 01 2014
Merrimack Pharmaceuticals to Present at Oppenheimer 25th Annual Healthcare Conference, Hold Analyst... Dec 01 2014
Insider Trading Alert - FCS, GDOT And MACK Traded By Insiders Nov 25 2014
Merrimack Pharmaceuticals Presents on Multiple Programs at the 26th EORTC-NCI-AACR Symposium on... Nov 21 2014
Merrimack Pharmaceuticals Presents on Multiple Programs at the 26th EORTC-NCI-AACR Symposium on... Nov 21 2014
Merrimack Pharmaceuticals' MM-398 Gets Fast Track Status Nov 20 2014
PharmaEngine Announces the Receipt of US FDA Fast Track Designation for MM-398 in Post-Gemcitabine... Nov 20 2014
The S&P failed to extend its 4-day winning streak following headlines out of the Fed Nov 19 2014
MERRIMACK PHARMACEUTICALS INC Financials Nov 19 2014
Insider Trading Alert - MACK, GWRE And CCOI Traded By Insiders Nov 19 2014
Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine... Nov 19 2014
Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine... Nov 19 2014
'Mad Money' Lightning Round: I'm Buy, Buy, Buying Biogen Nov 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK